Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

Fig. 4

Forest plots of direct and indirect comparison for progression-free survival (PFS) - II. A = Tax, B = Cap, C = Bev + Tax, D = Bev + Cap, E = Bev + Exm, F = Mot + Tax, H = Bev + Cap+Cyc, I = Bev + Cap+Vin, J = Bev + Tax+ Eve, K = Bev + Tax+Tre. Bev = bevacizumab, Cap = capecitabine, Tax = taxanes, Vin = vinorelbine, Cyc = cyclophosphamide, Exm = exemestane, Eve = everolimus, Tre = trebananib, Mot = motesanib. HR [95%CI] = hazard ratio with 95% confidence interval, NA = not applicable

Back to article page
\